98 related articles for article (PubMed ID: 14580251)
1. Positron emitting 18F-2-deoxy-2-fluoro-D-glucose: potential hot new therapy.
Mortimer JE; Taylor ME
Breast Cancer Res; 2003; 5(6):329-31. PubMed ID: 14580251
[TBL] [Abstract][Full Text] [Related]
2. Positron emission tomography agent 2-deoxy-2-[18F]fluoro-D-glucose has a therapeutic potential in breast cancer.
Moadel RM; Nguyen AV; Lin EY; Lu P; Mani J; Blaufox MD; Pollard JW; Dadachova E
Breast Cancer Res; 2003; 5(6):R199-205. PubMed ID: 14580255
[TBL] [Abstract][Full Text] [Related]
3. Radiotherapeutic use of 2-deoxy-2-[18F]fluoro-D-glucose--a comment.
Meyer MA
Breast Cancer Res; 2004; 6(1):E2. PubMed ID: 14680488
[No Abstract] [Full Text] [Related]
4. Positherapy: targeted nuclear therapy of breast cancer with 18F-2-deoxy-2-fluoro-D-glucose.
Moadel RM; Weldon RH; Katz EB; Lu P; Mani J; Stahl M; Blaufox MD; Pestell RG; Charron MJ; Dadachova E
Cancer Res; 2005 Feb; 65(3):698-702. PubMed ID: 15705862
[TBL] [Abstract][Full Text] [Related]
5. 18F-2-fluoro-2-deoxy-d-glucose positron emission tomography in staging of locally advanced breast cancer.
van der Hoeven JJ; Krak NC; Hoekstra OS; Comans EF; Boom RP; van Geldere D; Meijer S; van der Wall E; Buter J; Pinedo HM; Teule GJ; Lammertsma AA
J Clin Oncol; 2004 Apr; 22(7):1253-9. PubMed ID: 15051773
[TBL] [Abstract][Full Text] [Related]
6. Positron emission tomography with 2-[18F]Fluoro-2-deoxy-D-glucose and 16alpha-[18F]fluoro-17beta-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy.
Mortimer JE; Dehdashti F; Siegel BA; Katzenellenbogen JA; Fracasso P; Welch MJ
Clin Cancer Res; 1996 Jun; 2(6):933-9. PubMed ID: 9816253
[TBL] [Abstract][Full Text] [Related]
7. [Clinical experience with positron emission tomography with 2-fluorine, 18F-2-deoxy-d-glucose used for the diagnosis of malignant breast neoplasms].
Tiutin L; Fadeev N; Ryzhkova D; Kostenikiv N; Arzumanov A; Savello V; Tlostanova M
Vestn Rentgenol Radiol; 2001; (6):14-8. PubMed ID: 11858029
[TBL] [Abstract][Full Text] [Related]
8. PET imaging in breast cancer.
Bombardieri E; Crippa F
Q J Nucl Med; 2001 Sep; 45(3):245-56. PubMed ID: 11788817
[TBL] [Abstract][Full Text] [Related]
9. Initial experience in small animal tumor imaging with a clinical positron emission tomography/computed tomography scanner using 2-[F-18]fluoro-2-deoxy-D-glucose.
Tatsumi M; Nakamoto Y; Traughber B; Marshall LT; Geschwind JF; Wahl RL
Cancer Res; 2003 Oct; 63(19):6252-7. PubMed ID: 14559811
[TBL] [Abstract][Full Text] [Related]
10. Feasibility of imaging photodynamic injury to tumours by high-resolution positron emission tomography.
Moore JV; Waller ML; Zhao S; Dodd NJ; Acton PD; Jeavons AP; Hastings DL
Eur J Nucl Med; 1998 Sep; 25(9):1248-54. PubMed ID: 9724373
[TBL] [Abstract][Full Text] [Related]
11. Feasibility of detecting hypoxia in experimental mouse tumours with 18F-fluorinated tracers and positron emission tomography--a study evaluating [18F]Fluoro-2-deoxy-D-glucose.
Bentzen L; Keiding S; Horsman MR; Falborg L; Hansen SB; Overgaard J
Acta Oncol; 2000; 39(5):629-37. PubMed ID: 11093372
[TBL] [Abstract][Full Text] [Related]
12. Serial 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP).
Specht JM; Tam SL; Kurland BF; Gralow JR; Livingston RB; Linden HM; Ellis GK; Schubert EK; Dunnwald LK; Mankoff DA
Breast Cancer Res Treat; 2007 Sep; 105(1):87-94. PubMed ID: 17268819
[TBL] [Abstract][Full Text] [Related]
13. Utility of positron emission tomography in sarcomas.
Schuetze SM
Curr Opin Oncol; 2006 Jul; 18(4):369-73. PubMed ID: 16721133
[TBL] [Abstract][Full Text] [Related]
14. [18F] 3-deoxy-3'-fluorothymidine positron emission tomography: alternative or diagnostic adjunct to 2-[18f]-fluoro-2-deoxy-D-glucose positron emission tomography in the workup of suspicious central focal lesions?
Halter G; Buck AK; Schirrmeister H; Wurziger I; Liewald F; Glatting G; Neumaier B; Sunder-Plassmann L; Reske SN; Hetzel M
J Thorac Cardiovasc Surg; 2004 Apr; 127(4):1093-9. PubMed ID: 15052207
[TBL] [Abstract][Full Text] [Related]
15. Effective radiotherapy of primary tumors and metastasis with 18F-2-deoxy-2-fluoro-D-glucose in C57BL/6 mice.
Caridad V; Arsenak M; Abad MJ; Martín R; Guillén N; Colmenter LF; Taylor P
Cancer Biother Radiopharm; 2008 Jun; 23(3):371-5. PubMed ID: 18593370
[TBL] [Abstract][Full Text] [Related]
16. Metabolic fate of 18F-FDG in mice bearing either SCCVII squamous cell carcinoma or C3H mammary carcinoma.
Kaarstad K; Bender D; Bentzen L; Munk OL; Keiding S
J Nucl Med; 2002 Jul; 43(7):940-7. PubMed ID: 12097467
[TBL] [Abstract][Full Text] [Related]
17. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS
PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451
[TBL] [Abstract][Full Text] [Related]
18. Positron-emission tomographic scanning of primary and metastatic breast carcinoma with the radiolabeled glucose analogue 2-deoxy-2-[18F]fluoro-D-glucose.
Wahl RL; Cody R; Hutchins G; Mudgett E
N Engl J Med; 1991 Jan; 324(3):200. PubMed ID: 1984203
[No Abstract] [Full Text] [Related]
19. Clinical oncological applications of Positron Emission Tomography (PET) using fluorine-18-fluoro-2-deoxy-D-glucose.
Giorgetti A; Volterrani D; Mariani G
Radiol Med; 2002 Apr; 103(4):293-318. PubMed ID: 12107381
[TBL] [Abstract][Full Text] [Related]
20. Implication of 18F-fluoro-2-deoxy-D-glucose positron emission tomography on management of carcinoma of unknown primary in the head and neck: a Danish cohort study.
Johansen J; Eigtved A; Buchwald C; Theilgaard SA; Hansen HS
Laryngoscope; 2002 Nov; 112(11):2009-14. PubMed ID: 12439171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
